Free Trial
NYSE:CLDI

Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

$1.16
0.00 (0.00%)
(As of 03:07 PM ET)
Today's Range
$1.15
$1.20
50-Day Range
$1.11
$1.86
52-Week Range
$1.01
$42.50
Volume
19,479 shs
Average Volume
148,322 shs
Market Capitalization
$59.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67

Calidi Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,336.8% Upside
$16.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.38) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.25 out of 5 stars

Medical Sector

773rd out of 927 stocks

Biological Products, Except Diagnostic Industry

136th out of 154 stocks

About Calidi Biotherapeutics

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO.

CLDI Stock Price History

CLDI Stock News Headlines

Prepare for a Recession Unlike Any Other
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
Calidi to Effect Reverse Stock Split
Prepare for a Recession Unlike Any Other
Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.
See More Headlines
Receive CLDI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/13/2024
Today
9/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.67
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+1,336.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50,000.00
Book Value
($2.32) per share

Miscellaneous

Free Float
33,355,000
Market Cap
$59.07 million
Optionable
N/A
Beta
0.60
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

CLDI Stock Analysis - Frequently Asked Questions

How have CLDI shares performed this year?

Calidi Biotherapeutics' stock was trading at $1.9840 on January 1st, 2024. Since then, CLDI stock has decreased by 41.5% and is now trading at $1.16.
View the best growth stocks for 2024 here
.

How were Calidi Biotherapeutics' earnings last quarter?

Calidi Biotherapeutics, Inc. (NYSE:CLDI) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($1.40) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.03.

When did Calidi Biotherapeutics' stock split?

Calidi Biotherapeutics's stock reverse split before market open on Monday, July 15th 2024. The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Calidi Biotherapeutics' major shareholders?

Top institutional shareholders of Calidi Biotherapeutics include CPR Investments Inc. (11.00%), RS Crum Inc. (0.52%) and Delta Investment Management LLC (0.41%).

How do I buy shares of Calidi Biotherapeutics?

Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:CLDI) was last updated on 9/16/2024 by MarketBeat.com Staff

From Our Partners